Wave Life Sciences plans two‑year WVE‑006 trial after FDA feedback
A one-year biomarker analysis could support accelerated approval while the same study runs toward possible full approval.
Adrian Kessler
A single two-year study could support full U.S. approval of WVE-006, as Wave Life Sciences, Inc. NASDAQWVE said Thursday it plans a one-year interim biomarker analysis for potential accelerated approval following an FDA meeting. Wave says the plan could avoid a separate confirmatory trial and create an earlier filing opportunity after one year, according to its Oct. 1 release.
The company said the FDA supports its existing liquid chromatography mass spectrometry assay for measuring healthy M-AAT and mutant Z-AAT proteins. Wave described alignment on key aspects of the pathway, but its Oct. 1 release did not specify the planned trial's patient count, control arm, biomarker thresholds or start date.
Wave is a Cambridge-based clinical-stage biotechnology company developing RNA medicines for inherited lung and liver disease and metabolic conditions.
Wave shares closed at US$3.70 on Nasdaq on Sept. 30, up 1.65 per cent as of 4 p.m. EDT on the NASDAQWVE quote page. The close predates Thursday's announcement; Wave expects its next WVE-006 data from a 600 mg monthly cohort in the fourth quarter of 2026.
The Interim Readout Will Depend on Protein Markers
Alpha-1 antitrypsin deficiency leaves too little protective AAT protein in the lungs and can cause mutant protein to build up in the liver, Wave explained on Oct. 1. WVE-006 is designed to edit RNA so patients produce healthy M-AAT while reducing mutant Z-AAT. The FDA-supported assay measures both proteins, giving the company a measurement method for its proposed interim analysis.
The early evidence comes from an open-label Phase 1b/2a study, which had no control arm. In a May 18 update, Wave described three dose cohorts of eight patients each. In the 400 mg monthly multidose group, M-AAT reached 58.7 per cent of total AAT, while Z-AAT fell 67.7 per cent from baseline, based on mean maximum protein readings.
Those protein changes show biological activity, but the study has no control arm and does not establish that WVE-006 prevents lung damage or liver disease. All reported adverse events in the May 18 update were mild or moderate, with no serious adverse events or clinically meaningful liver test elevations.
The FDA says accelerated approval can rely on a marker thought to predict benefit, but the company must still verify clinical benefit. A one-year protein readout would therefore be an earlier regulatory test, while the same planned study continues toward its two-year full-approval objective. FDA support for Wave's assay addresses a measurement question; it is not an approval of WVE-006.
“A registrational trial design that offers an efficient path to full approval, without the need for a separate confirmatory trial, is advantageous as we work to bring WVE-006 to the ~200,000 individuals living with Pi*ZZ AATD in the U.S. and Europe.”
Wave chief medical officer Christopher Wright said in the company's Oct. 1 release.
Read more: Telix Pharmaceuticals Limited gains FDA Fast Track for BiPASS imaging
Arrowhead Targets AATD Liver Disease
Arrowhead Pharmaceuticals Inc. NASDAQARWR provides a listed AATD comparison. Its investigational fazirsiran uses RNA interference to reduce mutant Z-AAT in liver disease, according to Arrowhead's April 2023 release. Wave's approach is designed to address both lung and liver manifestations, a claim that still needs testing against patient outcomes.
On Wednesday, the iShares Biotechnology ETF NASDAQIBB closed at US$210.53 on Nasdaq as of 4:00:01 p.m. EDT. Wave reported US$490.6 million in cash, equivalents and marketable securities at June 30 and expected its funds to last into the third quarter of 2028. That forecast covers the planned near-term WVE-006 readout, although Wave has not dated the registrational trial.
Read more: DBV Technologies submits peanut patch BLA for children aged 4 to 7
Wave expects the 600 mg monthly multidose results from RestorAATion-2 in the fourth quarter of 2026. Those data will show whether a higher monthly dose sustains the protein response it plans to test in the registrational study.
